請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17738
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林泰元(Thai-Yen Ling) | |
dc.contributor.author | Tze-Jung Chen | en |
dc.contributor.author | 陳姿蓉 | zh_TW |
dc.date.accessioned | 2021-06-08T00:42:48Z | - |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-14 | |
dc.identifier.citation | 1. Friedenstein Aj Fau - Chailakhyan, R.K., et al., Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation, 1974. 17(4): p. 331-40. 2. Bianco P Fau - Robey, P.G., P.J. Robey Pg Fau - Simmons, and P.J. Simmons, Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell, 2008. 2(4): p. 313-9. 3. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006. 8(4): p. 315-7. 4. Watt, S.M., et al., The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Br Med Bull, 2013. 108(1): p. 25-53. 5. Medzhitov, R. and C. Janeway, Jr., Innate immunity. N Engl J Med, 2000. 343(5): p. 338-44. 6. Janeway, C.A., Jr. and R. Medzhitov, Innate immune recognition. Annu Rev Immunol, 2002. 20: p. 197-216. 7. Krieger, M., The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol, 1997. 8(5): p. 275-80. 8. Hansson, G.K., Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circulation Research, 2002. 91(4): p. 281-291. 9. Yi, T. and S.U. Song, Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res, 2012. 35(2): p. 213-21. 10. Jiang, X.X., et al., Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 2005. 105(10): p. 4120-6. 11. Aggarwal, S. and M.F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2004. 105(4): p. 1815-1822. 12. Spaggiari, G.M., et al., MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 2009. 113(26): p. 6576-83. 13. Choi, H., et al., Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood, 2011. 118(2): p. 330-8. 14. Kim, J. and P. Hematti, Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol, 2009. 37(12): p. 1445-53. 15. Maggini, J., et al., Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One, 2010. 5(2): p. e9252. 16. Poggi, A., et al., Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors. The Journal of Immunology, 2005. 175(10): p. 6352-6360. 17. Spaggiari, G.M., et al., Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 2006. 107(4): p. 1484-90. 18. Rasmusson, I., et al., Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 2003. 76(8): p. 1208-13. 19. Sotiropoulou, P.A., et al., Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 2006. 24(1): p. 74-85. 20. Spaggiari, G.M., et al., Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 2008. 111(3): p. 1327-33. 21. Glennie, S., et al., Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 2005. 105(7): p. 2821-7. 22. Krampera, M., et al., Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 2006. 24(2): p. 386-98. 23. Augello, A., et al., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol, 2005. 35(5): p. 1482-90. 24. Corcione, A., et al., Human mesenchymal stem cells modulate B-cell functions. Blood, 2006. 107(1): p. 367-72. 25. Bernardo, M.E. and W.E. Fibbe, Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell, 2013. 13(4): p. 392-402. 26. Krampera, M., et al., Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 2003. 101(9): p. 3722-9. 27. Bouffi, C., et al., IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One, 2010. 5(12): p. e14247. 28. Nemeth, K., et al., Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A, 2010. 107(12): p. 5652-7. 29. Haddad, R. and F. Saldanha-Araujo, Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? Biomed Res Int, 2014. 2014: p. 216806. 30. Stagg, J. and J. Galipeau, Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med, 2013. 13(5): p. 856-67. 31. Wang, S., X. Qu, and R.C. Zhao, Clinical applications of mesenchymal stem cells. J Hematol Oncol, 2012. 5: p. 19. 32. Le Blanc, K., et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 2004. 363(9419): p. 1439-41. 33. Messina, C., et al., Prevention and treatment of acute GvHD. Bone Marrow Transplant, 2008. 41 Suppl 2: p. S65-70. 34. Polchert, D., et al., IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 2008. 38(6): p. 1745-55. 35. Gu, F., et al., Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol, 2014. 33(11): p. 1611-9. 36. Wang, D., et al., Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant, 2013. 22(12): p. 2267-77. 37. Wang D Fau - Li, J., et al., Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther, 2014. 16(2): p. R79. 38. Ciccocioppo, R., et al., Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut, 2011. 60(6): p. 788-98. 39. Quimby, J.M., et al., Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Research Therapy, 2013. 4(2): p. 48-48. 40. Forbes, G.M., et al., A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol, 2014. 12(1): p. 64-71. 41. Herrmann, R., et al., Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol, 2012. 95(2): p. 182-8. 42. Vanikar, A.V., et al., Cotransplantation of Adipose Tissue-Derived Insulin-Secreting Mesenchymal Stem Cells and Hematopoietic Stem Cells: A Novel Therapy for Insulin-Dependent Diabetes Mellitus. Stem Cells International, 2010. 2010: p. 582382. 43. Luk, F., et al., Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review. Expert Rev Clin Immunol, 2015. 11(5): p. 617-36. 44. Zhukareva, V., et al., Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli. Cytokine, 2010. 50(3): p. 317-21. 45. Samuelsson, H., et al., Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy, 2009. 11(2): p. 129-36. 46. Krampera, M., Mesenchymal stromal cell 'licensing': a multistep process. Leukemia, 2011. 25(9): p. 1408-14. 47. Duijvestein, M., et al., Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells, 2011. 29(10): p. 1549-58. 48. Francois, M., et al., Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy, 2012. 14(2): p. 147-52. 49. Moll, G., et al., Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells, 2014. 32(9): p. 2430-42. 50. Collins, E., et al., Differential efficacy of human mesenchymal stem cells based on source of origin. J Immunol, 2014. 193(9): p. 4381-90. 51. Siegel, G., et al., Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Medicine, 2013. 11(1): p. 146. 52. Lee, R.H., et al., TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A, 2014. 111(47): p. 16766-71. 53. Shi, M., Z.W. Liu, and F.S. Wang, Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol, 2011. 164(1): p. 1-8. 54. Alves, H., et al., A mesenchymal stromal cell gene signature for donor age. PLoS One, 2012. 7(8): p. e42908. 55. Beane, O.S., et al., Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One, 2014. 9(12): p. e115963. 56. Choi, J.S., et al., Effects of donor age, long-term passage culture, and cryopreservation on tonsil-derived mesenchymal stem cells. Cell Physiol Biochem, 2015. 36(1): p. 85-99. 57. Zaim, M., et al., Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells. Ann Hematol, 2012. 91(8): p. 1175-86. 58. Ma, S., et al., Immunobiology of mesenchymal stem cells. Cell Death Differ, 2014. 21(2): p. 216-25. 59. Liang, O.D., et al., Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells, 2011. 29(1): p. 99-107. 60. Opitz, C.A., et al., Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells, 2009. 27(4): p. 909-19. 61. Nemeth, K., Mesenchymal stem cell therapy for immune-modulation: the donor, the recipient, and the drugs in-between. Exp Dermatol, 2014. 23(9): p. 625-8. 62. Mamidi, M.K., et al., Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem, 2012. 113(10): p. 3153-64. 63. Luetzkendorf, J., et al., Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. Cytotherapy, 2015. 17(2): p. 186-98. 64. Williams, L.B., et al., Post-thaw non-cultured and post-thaw cultured equine cord blood mesenchymal stromal cells equally suppress lymphocyte proliferation in vitro. PLoS One, 2014. 9(12): p. e113615. 65. Najar, M., et al., Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy, 2009. 11(5): p. 570-83. 66. Xu, G., et al., The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells. Biochem Biophys Res Commun, 2007. 361(3): p. 745-50. 67. Djouad, F., et al., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 2007. 25(8): p. 2025-32. 68. Scheller, J., et al., The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta, 2011. 1813(5): p. 878-88. 69. Ke, F., et al., Autocrine interleukin-6 drives skin-derived mesenchymal stem cell trafficking via regulating voltage-gated Ca(2+) channels. Stem Cells, 2014. 32(10): p. 2799-810. 70. Liu, S., et al., Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res, 2011. 71(2): p. 614-24. 71. Touboul, C., et al., Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. Journal of Translational Medicine, 2013. 11. 72. Tsai, K.S., et al., Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology, 2011. 141(3): p. 1046-56. 73. Matysiak, M., et al., Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J Neuroimmunol, 2011. 233(1-2): p. 106-11. 74. Ma, D., et al., In vitro characterization of human hair follicle dermal sheath mesenchymal stromal cells and their potential in enhancing diabetic wound healing. Cytotherapy, 2015. 17(8): p. 1036-51. 75. Zhou, X., et al., Human Umbilical Cord-Derived Mesenchymal Stem Cells Improve Learning and Memory Function in Hypoxic-Ischemic Brain-Damaged Rats via an IL-8-Mediated Secretion Mechanism Rather than Differentiation Pattern Induction. Cell Physiol Biochem, 2015. 35(6): p. 2383-401. 76. Ren, G., et al., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2008. 2(2): p. 141-50. 77. Sundin, M., et al., No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica, 2007. 92(9): p. 1208-1215. 78. Mackensen, A., et al., Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother, 2000. 49(3): p. 152-6. 79. Trojahn Kolle, S.F., et al., Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use. Cytotherapy, 2013. 15(9): p. 1086-97. 80. Rubio-Azpeitia, E. and I. Andia, Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience. Muscles, Ligaments and Tendons Journal, 2014. 4(1): p. 52-62. 81. Singer, N.G. and A.I. Caplan, Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol, 2011. 6: p. 457-78. 82. An, Y.S., et al., Substance P stimulates the recovery of bone marrow after the irradiation. J Cell Physiol, 2011. 226(5): p. 1204-13. 83. Liu, X.B., et al., Angiopoietin-1 preconditioning enhances survival and functional recovery of mesenchymal stem cell transplantation. J Zhejiang Univ Sci B, 2012. 13(8): p. 616-23. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17738 | - |
dc.description.abstract | 間葉細胞(MSCs)在過去的研究中被證實能調節生物體內的免疫平衡以適應環境改變,並且能有效地抑制過度的發炎反應。而這些功能使得MSCs在近年來逐漸發展成為細胞藥物,並且被廣泛地運用在臨床治療研究當中。研究指出,細胞藥物會由於來源、捐贈者、培養環境等各種因素,造成治療功能的差異。然而MSCs作為一個細胞藥物,目前並沒有一套標準的評估方式可以判斷MSCs的品質。因此,我們的目標是建立一個標準的in vitro模式以評估MSCs的免疫調節功能,並找到與其相關的功能標記(functional markers)。在我們的研究中利用抗體anti-CD3/28活化小鼠脾細胞的增生,結果發現胎盤絨毛膜蛻膜間葉細胞(placenta-choriodecidual derived mesenchymal stromal cells, pcMSCs) 能有效地抑制脾細胞增生,並且其抑制能力隨著細胞比例增加而上升。我們因此利用pcMSCs對小鼠脾細胞增生的抑制程度,作為評估pcMSCs免疫調控的標準。在評估的過程中,我們發現不同批次的差異以及冷凍保存細胞都會對pcMSCs造成功能影響。其中,來自捐贈者N166和剛解凍的pcMSCs都無法抑制小鼠脾細胞的增殖。由於MSCs可以透過各種細胞激素的分泌及受體表現,來達到免疫調控的能力。我們因此透過RT-PCR評估不同pcMSCs之間免疫調控因子的mRNA表現,研究結果發現功能正常的pcMSCs具有較高的IL-6和COX2表現量。在蛋白質表現部分,ELISA試驗證實psMSCs的IL-6分泌量,與其對脾細胞的抑制能力呈現正相關性。而Western blot試驗則顯示正常功能的pcMSCs具有較高的COX2表現量。此外,我們發現利用胎牛血清(FBS)對功能缺陷的pcMSCs進行培養,能有效地恢復其免疫調控功能。我們的研究證實小鼠脾細胞增生模式能有效地幫助我們評估pcMSCs免疫調控功能的差異,並且IL6和COX2等因子具有作為pcMSCs功能標記的潛力。 | zh_TW |
dc.description.abstract | Mesenchymal stromal cells (MSCs) are multipotent progenitor cells which are considered a promising tool for cell therapy in recent years. MSCs have been identified to possess immune-modulatory functions on inhibiting pro-inflammatory immune responses and modifying tissue homeostasis to adopt enhancing anti-inflammatory phenotype. According to these properties, they are currently being administrated to patients in clinical trials including graft-versus-host disease (GvHD), bone/cartilage disease or heart disease. Different sources, donors and culture conditions significantly influence the therapeutic potential of MSCs. However, there are no appropriate potency assay to predict the efficacy of MSCs before clinical use. Therefore, we aimed to create a standardized in vitro assay and find potential functional markers to evaluate the potency of pcMSCs. In this study, we stimulated mouse splenocytes proliferation using anti-CD3/28 and co-cultured splenocytes with placenta-choriodecidual derived mesenchymal stromal cells (pcMSCs) which exhibited dose-dependently ability to suppress splenocytes proliferation. We thus measured immune-modulatory efficacy of pcMSCs with this in vitro assay. Results showed that different batch and cryopreservation would affect pcMSCs. Batch N166 and freshly thawed pcMSCs have impaired immunosuppression ability. RT-PCR assays of pcMSCs shown normal pcMSCs have significantly higher level of IL-6 and COX2 mRNA compared to impaired pcMSCs. Protein levels measured by ELISA and western blot showed the same result. Also, we found out that culturing impaired pcMSCs with FBS could reversed the immunosuppressing properties effectively. Our study indicated that the potency of pcMSCs could be evaluated through mouse splenocytes proliferation assay. Importantly, IL6 and COX2 would be potential functional markers of pcMSCs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:42:48Z (GMT). No. of bitstreams: 1 ntu-104-R02443002-1.pdf: 2701957 bytes, checksum: cce2aec0330506020f2504a569a108de (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 中文摘要 iii Abstract iv Chapter 1 Introduction 1 1.1 Mesenchymal stromal cells (MSCs) 2 1.2 Placenta choriodecidual-derived mesenchymal stromal cells (pcMSC) 2 1.3 The immune system of human 3 1.4 The immune-modulatory ability of MSCs 5 1.5 The interaction of MSCs and T cells 6 1.6 Clinical applications of MSCs 7 1.7 in vitro potency assay of MSCs 9 1.8 Aims 11 Chapter 2 Materials and Methods 12 2.1 Animals 13 2.2 Human placenta chrionic-derived mesenchymal stromal cells (pcMSCs) 13 2.3 Mouse T cells 14 2.4 CFSE labeling 15 2.5 Splenocytes proliferation assay 15 2.6 Quantitative real time PCR 16 2.7 Enzyme-linked immunosorbent assay (ELISA) 16 2.8 Western blotting 17 2.9 Flow cytometry 18 2.10 Statistical analysis 18 Chapter 3 Results 19 3.1 pcMSCs dose-dependently suppress mouse splenocytes proliferation. 20 3.2 Different batch of pcMSCs show variable immune-modulatory efficacy 21 3.3 Cryopreservation affect the immune-modulatory ability of pcMSCs 23 3.4 Immune-modulatory related factors in pcMSCs changed with inflammatory cytokines stimulation 24 3.5 The expression of immuno-modulatory related factors increased after co-cultured with mouse splenocytes 25 3.6 The protein level IL6-, IL-8 and COX2 have positive correlation to the immuno-modulatory ability of pcMSCs 26 3.7 Inflammatory cytokines priming have no significant effect to pcMSCs in the mouse splenocytes proliferation assay 28 3.8 FBS can efficiently reverse the immuno-modulatory ability of impaired pcMSCs 28 3.9 Mouse splenocytes proliferation assay could be used to evaluate different sources MSCs 29 Chapter 4 Discussion 31 Chapter 5 Conclusions 41 Chapter 6 Figures 43 Chapter 7 References 66 | |
dc.language.iso | en | |
dc.title | 胎盤絨毛膜蛻膜間葉細胞效能評估之研究 | zh_TW |
dc.title | The Potency Evaluation of Human Placenta Choriodecidual-derived Mesenchymal Stromal Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳耀昌,林琬琬,莊雅惠,黃彥華 | |
dc.subject.keyword | 胎盤絨毛膜蛻膜間葉細胞,效能評估,功能標記,細胞藥物,免疫調控, | zh_TW |
dc.subject.keyword | Placenta-choriodecidual derived mesenchymal stromal cells,Potency eveluation,Functional marker,Cell drug,Immune modulation, | en |
dc.relation.page | 73 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2015-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。